SYRE Spyre Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model redesigned as clinical stage biotech focused on next-generation monoclonal antibodies for IBD and immune-mediated diseases
• • Emphasis on half-life extended antibodies aiming for less frequent, self-administered subcutaneous injections

Risk Factors

• • Legal risk from increased costs to comply with Nasdaq listing rules and SEC requirements post going public
• • Macroeconomic impact of $2.0M lease termination fee for Austin office abandonment creating liquidity pressure

Management Discussion & Analysis

• • No revenue reported in FY 2026, focus on pre-clinical stage asset acquisition and licensing
• • No profitability or margin data provided due to early-stage operations and recent acquisitions

Risk Factors

• • New material weakness in internal controls discovered Q4 2024 led to restatements of prior net loss per share disclosures
• • Going concern risk heightened by potential difficulty raising capital amid macroeconomic volatility and intensified biotech funding competition

What are the latest SYRE SEC filings in 2026?

Spyre Therapeutics, Inc. (SYRE) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 16, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did SYRE file its most recent 10-K annual report?

Spyre Therapeutics, Inc. (SYRE) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view SYRE 10-Q quarterly reports?

Spyre Therapeutics, Inc. (SYRE)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every SYRE 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has SYRE filed recently?

Spyre Therapeutics, Inc. (SYRE)'s most recent 8-K was filed on April 16, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find SYRE insider trading activity (Form 4)?

SignalX aggregates every SYRE Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does SYRE file with the SEC?

Spyre Therapeutics, Inc. (SYRE) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new SYRE filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Spyre Therapeutics, Inc. (SYRE).

What is SYRE's SEC CIK number?

Spyre Therapeutics, Inc. (SYRE)'s SEC CIK (Central Index Key) number is 1636282. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1636282 to look up all SYRE filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find SYRE return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Spyre Therapeutics, Inc. (SYRE) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.